[ad_1] Presidential Symposium 3 Not only is pembrolizumab significantly more tolerable than standard chemotherapy, but it also increases overall survival in advanced head and neck cancers and the expression of PD-L1 ≥ …
Read More »ESMO 2018: Initial Immunotherapy Extends Survival in Cancers of Head and Neck
